Sponge-gel-supported histoculture drug-response assay for head and neck cancer: Correlations with clinical response to cisplatin

K. T. Robbins, K. M. Connors, Anna Maria Storniolo, C. Hanchett, R. M. Hoffman

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objective: Sponge-gel-supported histoculture drug-response assay (SSHDRA) represents a promising method to determine chemosensitivity of solid tumors. To determine whether the assay correlates clinically, we compared the in vivo and in vitro effects of cisplatin in 23 of 26 patients with head and neck cancers. Design: The criterion for in vitro sensitivity to cisplatin was an 84% or greater inhibition by cisplatin of the number of tritiated thymidine- incorporating cells of the histocultured tumors compared with untreated control culture preparations, as measured by means of histologic autoradiography. Comparisons were made with clinical responses, ie, complete response, partial response, or no response. Patients: The study was carried out in patients with head and neck cancers and comprised 21 patients with squamous-cell carcinoma, three patients with other carcinomas, and two patients with sarcoma. Results: Ten of 12 patients with in vitro-sensitive tumors had either complete or partial response clinically. The overall accuracy of the SSHDRA was 74% in this correlative clinical trial; the predictive-positive value was 83%, the sensitivity was 71%, and the specificity was 78%. Seven of 11 patients with in vitro-resistant tumors demonstrated no response for a predictive-negative value of 64%. Conclusions: We conclude that the SSHDRA shows a high correlation for tumors that demonstrate both in vivo drug resistance and sensitivity. The in vitro-like maintenance of three-dimensional tissue architecture of the tumors in histoculture probably contributes to high clinical predictivity of drug response of the SSHDRA. The data support further comparisons to determine the clinical usefulness of the SSHDRA for identifying complete and partial responders to chemotherapy.

Original languageEnglish (US)
Pages (from-to)288-292
Number of pages5
JournalArchives of Otolaryngology - Head and Neck Surgery
Volume120
Issue number3
StatePublished - 1994
Externally publishedYes

Fingerprint

Porifera
Head and Neck Neoplasms
Cisplatin
Gels
Pharmaceutical Preparations
Neoplasms
Autoradiography
Drug Resistance
Sarcoma
Thymidine
Squamous Cell Carcinoma
Maintenance
In Vitro Techniques
Clinical Trials
Carcinoma
Drug Therapy

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Sponge-gel-supported histoculture drug-response assay for head and neck cancer : Correlations with clinical response to cisplatin. / Robbins, K. T.; Connors, K. M.; Storniolo, Anna Maria; Hanchett, C.; Hoffman, R. M.

In: Archives of Otolaryngology - Head and Neck Surgery, Vol. 120, No. 3, 1994, p. 288-292.

Research output: Contribution to journalArticle

@article{77f3da7d87854cd49a412f007ad0a603,
title = "Sponge-gel-supported histoculture drug-response assay for head and neck cancer: Correlations with clinical response to cisplatin",
abstract = "Objective: Sponge-gel-supported histoculture drug-response assay (SSHDRA) represents a promising method to determine chemosensitivity of solid tumors. To determine whether the assay correlates clinically, we compared the in vivo and in vitro effects of cisplatin in 23 of 26 patients with head and neck cancers. Design: The criterion for in vitro sensitivity to cisplatin was an 84{\%} or greater inhibition by cisplatin of the number of tritiated thymidine- incorporating cells of the histocultured tumors compared with untreated control culture preparations, as measured by means of histologic autoradiography. Comparisons were made with clinical responses, ie, complete response, partial response, or no response. Patients: The study was carried out in patients with head and neck cancers and comprised 21 patients with squamous-cell carcinoma, three patients with other carcinomas, and two patients with sarcoma. Results: Ten of 12 patients with in vitro-sensitive tumors had either complete or partial response clinically. The overall accuracy of the SSHDRA was 74{\%} in this correlative clinical trial; the predictive-positive value was 83{\%}, the sensitivity was 71{\%}, and the specificity was 78{\%}. Seven of 11 patients with in vitro-resistant tumors demonstrated no response for a predictive-negative value of 64{\%}. Conclusions: We conclude that the SSHDRA shows a high correlation for tumors that demonstrate both in vivo drug resistance and sensitivity. The in vitro-like maintenance of three-dimensional tissue architecture of the tumors in histoculture probably contributes to high clinical predictivity of drug response of the SSHDRA. The data support further comparisons to determine the clinical usefulness of the SSHDRA for identifying complete and partial responders to chemotherapy.",
author = "Robbins, {K. T.} and Connors, {K. M.} and Storniolo, {Anna Maria} and C. Hanchett and Hoffman, {R. M.}",
year = "1994",
language = "English (US)",
volume = "120",
pages = "288--292",
journal = "JAMA Otolaryngology - Head and Neck Surgery",
issn = "2168-6181",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Sponge-gel-supported histoculture drug-response assay for head and neck cancer

T2 - Correlations with clinical response to cisplatin

AU - Robbins, K. T.

AU - Connors, K. M.

AU - Storniolo, Anna Maria

AU - Hanchett, C.

AU - Hoffman, R. M.

PY - 1994

Y1 - 1994

N2 - Objective: Sponge-gel-supported histoculture drug-response assay (SSHDRA) represents a promising method to determine chemosensitivity of solid tumors. To determine whether the assay correlates clinically, we compared the in vivo and in vitro effects of cisplatin in 23 of 26 patients with head and neck cancers. Design: The criterion for in vitro sensitivity to cisplatin was an 84% or greater inhibition by cisplatin of the number of tritiated thymidine- incorporating cells of the histocultured tumors compared with untreated control culture preparations, as measured by means of histologic autoradiography. Comparisons were made with clinical responses, ie, complete response, partial response, or no response. Patients: The study was carried out in patients with head and neck cancers and comprised 21 patients with squamous-cell carcinoma, three patients with other carcinomas, and two patients with sarcoma. Results: Ten of 12 patients with in vitro-sensitive tumors had either complete or partial response clinically. The overall accuracy of the SSHDRA was 74% in this correlative clinical trial; the predictive-positive value was 83%, the sensitivity was 71%, and the specificity was 78%. Seven of 11 patients with in vitro-resistant tumors demonstrated no response for a predictive-negative value of 64%. Conclusions: We conclude that the SSHDRA shows a high correlation for tumors that demonstrate both in vivo drug resistance and sensitivity. The in vitro-like maintenance of three-dimensional tissue architecture of the tumors in histoculture probably contributes to high clinical predictivity of drug response of the SSHDRA. The data support further comparisons to determine the clinical usefulness of the SSHDRA for identifying complete and partial responders to chemotherapy.

AB - Objective: Sponge-gel-supported histoculture drug-response assay (SSHDRA) represents a promising method to determine chemosensitivity of solid tumors. To determine whether the assay correlates clinically, we compared the in vivo and in vitro effects of cisplatin in 23 of 26 patients with head and neck cancers. Design: The criterion for in vitro sensitivity to cisplatin was an 84% or greater inhibition by cisplatin of the number of tritiated thymidine- incorporating cells of the histocultured tumors compared with untreated control culture preparations, as measured by means of histologic autoradiography. Comparisons were made with clinical responses, ie, complete response, partial response, or no response. Patients: The study was carried out in patients with head and neck cancers and comprised 21 patients with squamous-cell carcinoma, three patients with other carcinomas, and two patients with sarcoma. Results: Ten of 12 patients with in vitro-sensitive tumors had either complete or partial response clinically. The overall accuracy of the SSHDRA was 74% in this correlative clinical trial; the predictive-positive value was 83%, the sensitivity was 71%, and the specificity was 78%. Seven of 11 patients with in vitro-resistant tumors demonstrated no response for a predictive-negative value of 64%. Conclusions: We conclude that the SSHDRA shows a high correlation for tumors that demonstrate both in vivo drug resistance and sensitivity. The in vitro-like maintenance of three-dimensional tissue architecture of the tumors in histoculture probably contributes to high clinical predictivity of drug response of the SSHDRA. The data support further comparisons to determine the clinical usefulness of the SSHDRA for identifying complete and partial responders to chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0028230343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028230343&partnerID=8YFLogxK

M3 - Article

C2 - 8123238

AN - SCOPUS:0028230343

VL - 120

SP - 288

EP - 292

JO - JAMA Otolaryngology - Head and Neck Surgery

JF - JAMA Otolaryngology - Head and Neck Surgery

SN - 2168-6181

IS - 3

ER -